Group A n = 9 | Group B n = 9 | p-value | |
Sex (females/males) | 4/5 | 4/6 | 0.26 |
Disease onset (years) | 7.9 ± 0.8 | 13.3 ± 0.7 | 0.11 |
Age (years) | 62.6 ± 2.8 | 79.1 ± 1.5 | 0.28 |
Stage according to Hoehn & Yahr scale | 3 | 4 | 0.6 |
Schwab & England score (mean ± SD and n in each %) | 62.0 ± 2.3 | 45.2 ± 3.1 | <0.05 |
3 (60%) | 5 (50%) | ||
6 (70%) | 4 (40%) | ||
Disease duration (years) OFF-time (h/12 h) | 8.0 ± 0.4 | 13.0 ± 0.6 | 0.09 |
5.7 ± 0.2 | 6.4 ± 0.3 | 0.27 | |
Levodopa | 723 ± 15 | 920 ± 12 | 0.16 |
ON-time with dyskinesia (h/12 h) | 3.5 ± 0.9 | 3.4 ± 0.2 | 0.4 |
Non-motor symptoms (NMSS) | 44.2 ± 2.1 | 62.8 ± 3.2 | 0.1 |